All News
Filter News
Found 463 articles
-
Since its $63 billion acquisition of Allergan in 2019, AbbVie has become one of the leading companies developing therapies for migraine.
-
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
4/27/2022
Pfizer Inc. and Biohaven Pharmaceutical Holding Company Ltd. announced that the European Commission has granted marketing authorization for VYDURA®, a calcitonin gene-related peptide receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month.
-
Sosei Heptares to Embed Agile Operating Model and Enhance its Translational Medicine Capabilities through Strategic Collaboration with Weatherden
4/26/2022
Sosei Group Corporation announces a strategic collaboration with Weatherden, a pioneering clinical development consulting group.
-
Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directorse
4/22/2022
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, announced the appointment of Amrit Ray, M.D., M.B.A. to the company’s Board of Directors.
-
Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update
4/14/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced two updates regarding Nurtec® ODT (rimegepant), the only FDA-approved medication to both treat and prevent migraine attacks in adults.
-
Biohaven Real-World Study Highlights Increased Healthcare Utilization Among Americans with Episodic Migraine having Higher Levels of Migraine-Related Disability
4/14/2022
Biohaven Pharmaceutical Holding Company Ltd. announced the publication of new real-world research showing that as migraine-related disability increases, healthcare utilization also increases among Americans with episodic migraine.
-
Osmol Therapeutics Announces Closing of Series A-1 Funding to Advance the Clinical Development of the First Therapy to Prevent Chemotherapy-Induced Neuropathy
4/12/2022
Osmol Therapeutics today announced that it has closed the first $5.2 million tranche of a $7.5 million Series A-1 financing led by Koax Investment Partners.
-
The American Academy of Neurology Annual Meeting (AAN) was held virtually and in-person in Seattle from April 2-7. Here’s a look at some of the highlights.
-
Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis
4/7/2022
Biohaven announced the presentation of important findings pertaining to the benefit of Nurtec® ODT (rimegepant) in decreasing the burden of opioid use among a significant number of migraine patients in real world clinical practice.
-
Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal
4/1/2022
Biohaven Pharmaceutical Holding Company Ltd., announced that data from a Phase 1, single-center, open-label study evaluating the excretion of a single dose of rimegepant 75 mg in the human milk of healthy lactating women was published in the peer-reviewed journal, Breastfeeding Medicine, the official journal of the Academy of Breastfeeding Medicine.
-
Biohaven Data at 2022 American Academy of Neurology (AAN) Annual Meeting Demonstrate Leadership in Migraine and Commitment to Advancing Potential New Therapeutic Options in Neurological Diseases
3/31/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 13 abstracts, including two oral presentations, will be featured at the 2022 American Academy of Neurology (AAN) annual meeting being held April 2-7 in Seattle, WA and virtually from April 24-26.
-
Artizan Biosciences Announces Issuance of New U.S. Patent to Cover Proprietary Discovery Platform
3/29/2022
Artizan Biosciences, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,299,790 that broadens the use of the company’s proprietary IgA-SEQ™ discovery platform.
-
Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage of its Evolution
3/24/2022
Sosei Group Corporation confirms that a series of Executive Management changes have been approved at the Company’s 32nd Shareholders’ Meeting today and are effective immediately.
-
Biohaven Pharmaceutical Holding announced the acquisition of Channel Bio and new licensing rights to a spinal muscle atrophy drug from Bristol Myers Squibb.
-
Biohaven and Pfizer Receive Positive CHMP Opinion for Migraine Treatment
2/25/2022
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) and Pfizer Inc. (NYSE: PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for rimegepant.
-
BIOHAVEN REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS
2/25/2022
Biohaven Pharmaceutical Holding Company Ltd. today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a review of accomplishments during 2021 and anticipated upcoming milestones.
-
Biohaven Licenses Taldefgrobep Alfa, a Phase 3-Ready Anti-Myostatin Adnectin for Spinal Muscular Atrophy (SMA), from Bristol Myers Squibb
2/25/2022
Biohaven Pharmaceutical announced today that it entered into a worldwide license agreement with Bristol Myers Squibb (NYSE: BMY) for the development and commercialization rights to taldefgrobep alfa, a novel, Phase 3-ready anti-myostatin adnectin.
-
Biohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences
2/25/2022
Acquisition of next-generation Kv7 channel activators for target indications including epilepsy, pain disorders and affective disorders.
-
Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT
2/22/2022
Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced enrollment in a Phase 2/3 clinical trial assessing the efficacy and safety of Nurtec® ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis (CRS) with or without nasal polyps.
-
BIOHAVEN TO REPORT FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND RECENT BUSINESS DEVELOPMENTS ON FEBRUARY 25, 2022
2/16/2022
Biohaven Pharmaceutical Holding Company Ltd. will hold its upcoming fourth quarter and year end 2021 earnings call and webcast, reporting financial results for the quarter ended December 31, 2021 and provide a review of recent accomplishments and anticipated upcoming milestones, on Friday February 25, 2022 at 8:30 a.m. ET.